A5059060277- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- T-cell and B-cell Immunology
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Gastrointestinal Tumor Research and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Prenatal Screening and Diagnostics
- Parasitic infections in humans and animals
- Biosimilars and Bioanalytical Methods
- Viral-associated cancers and disorders
- 3D Printing in Biomedical Research
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Neutropenia and Cancer Infections
- Rheumatoid Arthritis Research and Therapies
Virginia Commonwealth University
2024-2025
Tufts Medical Center
2016-2020
Memorial Sloan Kettering Cancer Center
2019
Tufts University
2018
Molecular Oncology (United States)
2017
National Institutes of Health
2014-2015
National Heart Lung and Blood Institute
2015
MedStar Washington Hospital Center
2014
Johns Hopkins Medicine
2012
Johns Hopkins University
2012
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index (SDI) is the accepted measure permanent organ damage in systemic lupus erythematosus (SLE). We analyzed data from a large SLE cohort to identify variables associated with rates accrual as measured by SDI.The study included 2,054 patients (92% female, 56% white, and 37% African American) mean age at diagnosis 33 years. SDI score was calculated retrospectively time entry prospectively...
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
Natural killer (NK) cells are phenotypically and functionally diverse lymphocytes that recognize kill cancer cells. The susceptibility of target to NK cell-mediated cytotoxicity depends on the strength balance regulatory (activating/inhibitory) ligands expressed cell surface. We performed gene expression arrays determine patterns associated with B-cell non-Hodgkin lymphoma (b-NHL). Microarray analyses revealed significant upregulation a multitude NK-activating costimulatory across varied...
Pancreatic cancer continues to have high mortality despite the development of many chemotherapeutic agents. The 5-year relative survival for stage IV patients is less than 3%. This urgent unmet need warrants novel and active therapeutic agents, which focus both on targeting cells modifying microenvironment cells. Areas covered: In this article, authors review masitinib, a tyrosine kinase inhibitor numerous targets, including c-Kit, PDGFR FGFR. covers its from bench clinical trials assessing...
2576 Background: DPYD gene encodes DPD, the rate-limiting enzyme responsible for catabolism of 5-FU and is > 85% elimination. Deficiency DPD due to polymorphism gives rise severe AEs from reduced catabolism. This pharmacogenetic ‘DPD syndrome’ manifests typically as or fatal diarrhea, mucositis/stomatitis, myelosuppression even rare toxicities, such hepatitis, encephalopathy acute cardiac ischemia following first second dose 5-FU. The most compelling reason introduce routine testing avoid in...
e20701 Background: Bone metastases are a significant cause of morbidity leading to skeletal related events (SREs) in patients with advanced breast cancer. Denosumab and zoledronic acid (ZA) used prevent SREs. Unlike ZA, denosumab is not cleared by the kidneys therefore, less likely kidney impairment. Methods: Data on cancer treated at MedStar institutions from October 1, 2010 June 30, 2013 were collected. Patients bone who had previously been ZA switched included this retrospective study....
e23513 Background: There is a wide variability in pharmacokinetics, pharmacodynamics & tolerance of anticancer drugs based on ethnicity. Myelosuppression common pts with cancer who receive chemotherapy and contributes to therapy-induced morbidity mortality. GIST rare (~1% GI cancers). Imatinib used the neoadjuvant, adjuvant metastatic setting. The purpose this study was investigate difference imatinib among different ethnicities when treated for any Methods: Pts from July 2005 - Jan 2018...
Background Deep and durable hematologic remissions following RA-ASCT are associated with improved organ function extended overall survival in AL amyloidosis. While depth of response by standard criteria important, this study assessed additional factors that influence RR time to RR. Methods All patients (pts) renal involvement undergoing at Memorial Sloan Kettering Cancer Center between January 1, 2007 December 31, 2016 were included. Pts follow up Results Sixty-four meeting the inclusion...